Sheref A. Elseidy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sheref A. Elseidy has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ayman Elbadawi
Division of Cardiology, Christus Good Shepherd Medical Center, Longview, USA
2 shared publications - Mamas Andreas Mamas
Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, United Kingdom; National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, United Kingdom
2 shared publications - Mohamed Hamed
Florida Atlantic University
2 shared publications - Anthony A. Bavry
University of Texas Southwestern Medical Center
1 shared publication Asmaa Ahmed
Department of Internal Medicine, Rochester General Hospital, NY (A.A.).
1 shared publication- Dharam Jaydeep Kumbhani
Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX
1 shared publication
Latest Publications
- 1 January 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (1) , e014681
Outcomes of Intracoronary Imaging–Guided PCI With Optimal Versus Suboptimal Results: A Meta-Analysis
- 1 January 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (1) , e014681
Outcomes of Intracoronary Imaging–Guided PCI With Optimal Versus Suboptimal Results: A Meta-Analysis
- Open Access
- 29 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e035535
Immediate Versus Staged Complete Revascularization for Patients With ST‐Segment–Elevation Myocardial Infarction and Multivessel Disease: A Network Meta‐Analysis of Randomized Trials
Background: The comparative outcomes with immediate, staged in‐hospital, and staged out‐of‐hospital complete revascularization for patients with ST‐segment–elevation myocardial infarction and multivessel disease remain unclear. Methods and Results: An electronic search of MEDLINE, SCOPUS, and Cochrane databases was performed through August 2023 for randomized trials evaluating immediate, staged in‐hospital, and staged out‐of‐hospital complete revascularization for patients with ST‐segment–elevation myocardial infarction and multivessel disease. The primary outcome was major adverse cardiac events (MACEs). The final analysis included 9 trials with 4270 patients. The weighted follow‐up duration was 13.8 months. On pairwise meta‐analysis, there were no statistically significant differences between immediate versus staged nonculprit percutaneous coronary intervention (PCI) in MACEs (odds ratio, 0.79 [95% CI, 0.54–1.16]). Network meta‐analysis showed that there was no statistically significant difference in MACEs with staged in‐hospital nonculprit PCI (odds ratio, 1.29–[95% CI, 0.91–1.82]) compared with immediate nonculprit PCI, while there were higher odds of MACEs with out‐of‐hospital nonculprit PCI (odds ratio, 1.67–[95% CI, 1.21–2.30]) compared with immediate nonculprit PCI. Compared with immediate nonculprit PCI, there were higher odds of ischemia‐driven repeat revascularization with staged out‐of‐hospital nonculprit PCI (odds ratio, 2.26–[95% CI, 1.37–3.72]), but not with in‐hospital staged nonculprit PCI. There were no significant differences for the other outcomes among the 3 strategies. Conclusions: Among patients with ST‐segment–elevation myocardial infarction with multivessel disease, an immediate nonculprit PCI approach was associated with similar clinical outcomes to the staged nonculprit PCI approach. The staged out‐of‐hospital nonculprit PCI approach was associated with a higher incidence of MACEs compared with the other strategies, which was driven by higher risk for ischemia‐driven repeat revascularization.
- 29 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e035535
Open AccessImmediate Versus Staged Complete Revascularization for Patients With ST‐Segment–Elevation Myocardial Infarction and Multivessel Disease: A Network Meta‐Analysis of Randomized Trials
Background: The comparative outcomes with immediate, staged in‐hospital, and staged out‐of‐hospital complete revascularization for patients with ST‐segment–elevation myocardial infarction and multivessel disease remain unclear. Methods and Results: An electronic search of MEDLINE, SCOPUS, and Cochrane databases was performed through August 2023 for randomized trials evaluating immediate, staged in‐hospital, and staged out‐of‐hospital complete revascularization for patients with ST‐segment–elevation myocardial infarction and multivessel disease. The primary outcome was major adverse cardiac events (MACEs). The final analysis included 9 trials with 4270 patients. The weighted follow‐up duration was 13.8 months. On pairwise meta‐analysis, there were no statistically significant differences between immediate versus staged nonculprit percutaneous coronary intervention (PCI) in MACEs (odds ratio, 0.79 [95% CI, 0.54–1.16]). Network meta‐analysis showed that there was no statistically significant difference in MACEs with staged in‐hospital nonculprit PCI (odds ratio, 1.29–[95% CI, 0.91–1.82]) compared with immediate nonculprit PCI, while there were higher odds of MACEs with out‐of‐hospital nonculprit PCI (odds ratio, 1.67–[95% CI, 1.21–2.30]) compared with immediate nonculprit PCI. Compared with immediate nonculprit PCI, there were higher odds of ischemia‐driven repeat revascularization with staged out‐of‐hospital nonculprit PCI (odds ratio, 2.26–[95% CI, 1.37–3.72]), but not with in‐hospital staged nonculprit PCI. There were no significant differences for the other outcomes among the 3 strategies. Conclusions: Among patients with ST‐segment–elevation myocardial infarction with multivessel disease, an immediate nonculprit PCI approach was associated with similar clinical outcomes to the staged nonculprit PCI approach. The staged out‐of‐hospital nonculprit PCI approach was associated with a higher incidence of MACEs compared with the other strategies, which was driven by higher risk for ischemia‐driven repeat revascularization.